Biocon climbs on getting marketing authorization for Pebrilzo in EU
Biocon is currently trading at Rs. 366.55, up by 6.90 points or 1.92% from its previous closing of Rs. 359.65 on the BSE.
The scrip opened at Rs. 361.00 and has touched a high and low of Rs. 367.10 and Rs. 357.35 respectively. So far 14410 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 447.00 on 16-Jul-2026 and a 52 week low of Rs. 318.50 on 23-Oct-2026.
Last one week high and low of the scrip stood at Rs. 372.05 and Rs. 357.35 respectively. The current market cap of the company is Rs. 58440.83 crore.
The promoters holding in the company stood at 44.68%, while Institutions and Non-Institutions held 37.94% and 17.39% respectively.
Biocon has received marketing authorization from European Commission (EC) for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). The company’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach. This step follows its positive CHMP opinion on September 17, 2026.
